EPA-Approved SARS-CoV-2 Disinfectants
7 rows where "Date_on_List_N" is on date 2021-04-13 and Formulation_type contains "Dilutable" sorted by Formulation_type
json
Export this Data | Chart Risk Level by Product
Clear Chart
Add More Filters: Active_ingredient
ID
|
EPA_reg_num
|
Risk_level
|
Active_ingredient
|
Product_name
|
Company
|
Use_site
|
Surface_type
|
Contact_time
|
Formulation_type ▼
|
Follow_directions_for_this_virus
|
Date_on_List_N
|
Why_on_List_N
|
1099 |
6836-136 |
Increased Risk |
Quaternary ammonium |
Lonza Formulation S-18F |
Arxada, LLC |
Healthcare; Institutional; Residential |
Hard Nonporous (HN) |
1.0 minutes |
Dilutable |
SARS-CoV-2 |
2021-04-13 |
Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1100 |
6836-140 |
Increased Risk |
Quaternary ammonium |
Lonza Formulation S-21F |
Arxada, LLC |
Healthcare; Institutional; Residential |
Hard Nonporous (HN) |
1.0 minutes |
Dilutable |
SARS-CoV-2 |
2021-04-13 |
Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1102 |
6836-77 |
Increased Risk |
Quaternary ammonium |
Lonza Formulation S-18 |
Arxada, LLC |
Healthcare; Institutional; Residential |
Hard Nonporous (HN) |
1.0 minutes |
Dilutable |
SARS-CoV-2 |
2021-04-13 |
Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1103 |
6836-381 |
Increased Risk |
Quaternary ammonium |
Lonzagard R-82G |
Arxada, LLC |
Healthcare; Institutional; Residential |
Hard Nonporous (HN) |
1.0 minutes |
Dilutable |
SARS-CoV-2 |
2021-04-13 |
Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1104 |
6836-139 |
Increased Risk |
Quaternary ammonium |
Lonza Formulation R-82F |
Arxada, LLC |
Healthcare; Institutional; Residential |
Hard Nonporous (HN) |
1.0 minutes |
Dilutable |
SARS-CoV-2 |
2021-04-13 |
Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1109 |
6836-75 |
Increased Risk |
Quaternary ammonium |
Lonza Formulation S-21 |
Arxada, LLC |
Healthcare; Institutional; Residential |
Hard Nonporous (HN) |
1.0 minutes |
Dilutable |
SARS-CoV-2 |
2021-04-13 |
Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1110 |
6836-78 |
Increased Risk |
Quaternary ammonium |
Lonza Formulation R-82 |
Arxada, LLC |
Healthcare; Institutional; Residential |
Hard Nonporous (HN) |
1.0 minutes |
Dilutable |
SARS-CoV-2 |
2021-04-13 |
Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |